CAS: 32955-21-8; Ethyl 2-Aminothiazole-5-Carboxylate

上下游产品

2-(叔丁氧酰胺)噻唑-5-甲酸乙酯 Ethyl 2-((Tert-Butoxycarbonyl)Amino)Thiazole-5-Carboxylate 302964-01-8

3-乙氧基丙烯酸乙酯置于n-溴代丁二酰亚胺(Nbs)体系中,用 1,4-二氧六环,水 用作溶剂,化学反应 1.5H,反应生成2-氨基噻唑-5-羧酸乙酯
参考文献:一种新的简便的2-氨基噻唑-5-羧酸酯的合成方法
标题:一种新的简便的2-氨基噻唑-5-羧酸酯的合成方法
摘要:已经开发出一种新的简便方法来合成2-氨基噻唑-5-羧酸盐.新方法涉及将β-乙氧基丙烯酸乙酯与n-溴琥珀酰亚胺(nbs)反应生成新的中间体α-溴-α-甲酰乙酸半缩醛.原位形成的半缩醛与硫脲的环化反应以60-98%的收率提供了2-氨基噻唑-5-羧酸盐.
Doi:10.1016/s0040-4039(01)00161-7

专利信息

专利号:WO-2011095125-A1
优先权日:2010-02-02
标 题:Synthesis methods and purification methods of dasatinib
发明人：YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
权利人:NAN JING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD; YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
摘要:Synthesis methods of dasatinib are provided, which comprise the following steps: reacting a compound of formula I with a compound of formula II to obtain a compound of formula III, and then connecting the compound of formula III with 2-chloro-6-methylaniline and 1-(2-hydroxyethyl)piperazine in any order to give dasatinib. Furthermore, purification methods of dasatinib are also provided.

专利号:US-9108954-B2
优先权日:2010-02-02
标 题:Synthesis process of dasatinib and intermediate thereof
发明人：YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
权利人:YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG; NAN JING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD
摘要:Synthesis process of dasatinib is disclosed, which includes the step of reacting the compound of formula I with that of formula II to obtain the compound of formula III. Also disclosed is the compound of formula III which is used as an intermediate for synthesizing dasatinib. The substituents of R1, R2, R3 or R4 in formulae I, II or III are defined as in the description.

专利号:US-2025296928-A1
优先权日:2021-10-19
标题:A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof
发明人：MARSEGLIA GIUSEPPE; CARUANA LORENZO; CANELLI TOMMASO; ZHAO XIANGLIN; WANG WENKE; ZHAO ZIQIANG; MANGOLIA STEFANIA
权利人:IOMX THERAPEUTICS AG
摘要:The present invention relates to a new scheme and process for the preparation of one specific SIK3 inhibiting compound known as (and described herein as) “E9†. Compound E9 has previously been described by the present applicant to show surprisingly superior drug-like properties, such as in respect of target-potency/specificity and ADMET/PK properties, compared to other prior art SIK3 inhibiting compound. The present invention also relates to novel intermediates used in such process of preparing compound E9, as well as to a new methodology used within the process of producing a characteristic key thiophene-based amino intermediate that is used to produce compound E9, and other related aspects as disclosed herein.

专利号:JP-H1087639-A
优先权日:1992-12-29
标题:Useful intermediates for the synthesis of compounds that inhibit retroviral protease

专利号:WO-2011095126-A1
优先权日:2010-02-02
标题:Synthesis process of dasatinib and intermediate thereof

专利号:CN-106046089-A
优先权日:2016-06-27
标 题 :A kind of synthesis method of treating primary or secondary leukemia drug decitabine